Summary: Thought Leader: Brad Thompson, Ph.D., Chairman, President and CEO, Oncolytics Biotech In this episode, Dr. Thompson talks about how biotech is making improvements in the standard of care, and the impact of Pharma 3.0. He also talks about his own experience taking REOLYSIN® through the drug development process, the genesis of Oncolytics Biotech, and shares some insights for biotech entrepreneurs. Play Podcast For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.
